ReviewOpen forum infectious diseases2024
The Global and Regional Prevalence of Hospital-Acquired Carbapenem-Resistant
Review in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Risk factors for carbapenem-resistant Klebsiella pneumoniae infection in hospitalized patients: a meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Risk factors for carbapenem-resistantFrontiers in public health · 2026Pooled it
- Antibiotic resistance and bacterial co-infections in COVID-19 patients in Iran: a systematic review and meta-analysis of hospitalized and non-hospitalized cases.BMC infectious diseases · 2025Pooled it
- Prevalence of genes encoding carbapenem-resistance in Klebsiella pneumoniae recovered from clinical samples in Africa: systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study.The Journal of infectious diseases · 2026Trial
- Small regulatory RNAs mediated regulation of virulence and host-pathogen interaction in the Gram-negative ESKAPE pathogens.Virulence · 2026Review
- Ceftazidime-Avibactam With or Without Aztreonam Versus Other Active Antimicrobials in the Treatment of Bloodstream Infections by Carbapenem-Resistant Klebsiella pneumoniae.Infectious diseases and therapy · 2026Article
- Carbapenem-ResistantMicroorganisms · 2026Review
- Incidence of carbapenemase-resistant isolates ofNew microbes and new infections · 2026Article
- Exploratory Genomic Characterisation of the Resistome, Virulome and Molecular Epidemiology of Multidrug-ResistantMicroorganisms · 2026Article
- Immunogenic Profiling Reveals Promising RV-Identified Antigens as Vaccine Candidates AgainstInternational journal of molecular sciences · 2026Article
- Multicenter Point-Prevalence Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Molecular Epidemiology ofMicroorganisms · 2026Article
- High burden of blaBMC microbiology · 2026Article
- Gut Colonisation and Multidrug-Resistant Urinary Tract Infections in Hospitalised Kidney Transplant Recipients: A Single-Centre Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Phage cocktails for the disinfection of carbapenem-resistant Klebsiella pneumoniae on high-touch surfaces in intensive care units.BMC microbiology · 2026Article
- A nomogram for predicting 30-day mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Prevalence, antimicrobial resistance, and associated factors of critical superbugs Klebsiella pneumoniae and Acinetobacter species among hospitalized patients in Northwest Ethiopia.BMC microbiology · 2026Article
- Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China.BMC microbiology · 2026Article
- Characterization of Proline-Rich Antimicrobial Peptides with SbmA Transporter-Dependent and Independent Antimicrobial Activity towardACS infectious diseases · 2026Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Due to scarce therapeutic options, hospital-acquired infections caused by Method: MEDLINE, Embase, PubMed, and Google Scholar were searched for studies reporting CRKP prevalence from inception to 30 March 2023. Data from eligible publications were extracted and subjected to meta-analysis to obtain global, regional, and country-specific estimates. To determine the cause of heterogeneity among the selected studies, prespecified subgroup analyses and meta-regression were also performed. Odds ratios of CRKP-associated risk factors were pooled by a DerSimonian and Laird random-effects method. Results: We retained 61 articles across 14 countries and territories. The global prevalence of CRKP among patients with KP infections was 28.69% (95% CI, 26.53%-30.86%). South Asia had the highest CRKP prevalence at 66.04% (95% CI, 54.22%-77.85%), while high-income North America had the lowest prevalence at 14.29% (95% CI, 6.50%-22.0%). In the country/territory level, Greece had the highest prevalence at 70.61% (95% CI, 56.77%-84.45%), followed by India at 67.62% (95% CI, 53.74%-81.79%) and Taiwan at 67.54% (95% CI, 58.65%-76.14%). Hospital-acquired CRKP infections were associated with the following factors: hematologic malignancies, corticosteroid therapies, intensive care unit stays, mechanical ventilations, central venous catheter implantations, previous hospitalization, and antibiotic-related exposures (antifungals, carbapenems, quinolones, and cephalosporins). Conclusions: Study findings highlight the importance of routine surveillance to control carbapenem resistance and suggest that patients with nosocomial KP infection have a very high prevalence of CRKP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.